Literature DB >> 33037981

Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism.

Yuhan Li1,2,3, Yansong Luan1,2, Jianning Li1,2, Hui Song1,2, Yan Li1,2, Hi Qi1, Bo Sun4, Peng Zhang4, Xianxian Wu3, Xing Liu3, Yanhui Yang1,2, Wufan Tao5, Lei Cai6, Zhiwei Yang7, Yi Yang8,9.   

Abstract

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) and its complications has become an expanding health problem worldwide with limited therapeutic approaches. The current study was aiming to identify novel microRNA in the regulation of hepatic lipid metabolism in NAFLD. APPROCHES AND
RESULTS: Systematic screening of microRNA expression by high-throughput small RNA sequencing demonstrated that microRNA 199a-5p (miR-199a-5p) was significantly upregulated in high fat diet-induced steatosis mouse model, with the most abundant expression in adipose tissue. MST1 was further identified as the target gene for miR-199a with specific recognition at the 3' untranslated region with dural luciferase reporter assay. Delivery of miR-199a-5p with exosomes into mice aggravated liver lipid accumulation in hepatocytes, accompanied by down-regulation of hepatic MST1 expression and modulation of hepatic lipogenesis and lipolysis, including SREBP-1c, AMPK signaling cascades and the down-stream CPT1α and FASN. Conversely, administration of exosome containing anti-miR-199a-5p resulted in attenuated steotosis in mice fed on high fat diet. Importanly, miR-199a-5p-induced abnormal cellular lipid accumulation could be markedly reversed by overexpression of MST1.
CONCLUSION: miR-199a-5p might be an essentail regulator for hepatic lipid metabolism, possibly through its interction with MST1 and the subsequent signaling cascade. Thus, miR-199a-5p may serve as an important therapeutic target in the treatment of NAFLD.

Entities:  

Keywords:  Exosomes; MST1; NAFLD; miR-199a-5p

Year:  2020        PMID: 33037981     DOI: 10.1007/s12072-020-10096-0

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  48 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Am J Gastroenterol       Date:  2012-06       Impact factor: 10.864

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

3.  Adipose-derived exosomal MicroRNAs orchestrate gene regulation in the liver: Is this the missing link in nonalcoholic fatty liver disease?

Authors:  Hannelie Korf; Schalk van der Merwe
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 4.  From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Authors:  Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-20       Impact factor: 46.802

Review 5.  Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.

Authors:  Aijaz Ahmed; Robert J Wong; Stephen A Harrison
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-27       Impact factor: 11.382

Review 6.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

7.  Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver.

Authors:  Mara Monetti; Malin C Levin; Matthew J Watt; Mini P Sajan; Stephen Marmor; Brian K Hubbard; Robert D Stevens; James R Bain; Christopher B Newgard; Robert V Farese; Andrea L Hevener; Robert V Farese
Journal:  Cell Metab       Date:  2007-07       Impact factor: 27.287

Review 8.  New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Xu Zhang; Xuetao Ji; Qian Wang; John Zhong Li
Journal:  Protein Cell       Date:  2017-06-22       Impact factor: 14.870

Review 9.  Epigenetics in liver disease: from biology to therapeutics.

Authors:  Timothy Hardy; Derek A Mann
Journal:  Gut       Date:  2016-09-13       Impact factor: 23.059

10.  Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci.

Authors:  Stefan Stender; Julia Kozlitina; Børge G Nordestgaard; Anne Tybjærg-Hansen; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2017-04-24       Impact factor: 38.330

View more
  10 in total

Review 1.  Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease.

Authors:  Ji Sun; Dianbao Zhang; Yiling Li
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

2.  Knockout of circRNA single stranded interacting protein 1 (circRBMS1) played a protective role in myocardial ischemia-reperfusion injury though inhibition of miR-2355-3p/Mammalian Sterile20-like kinase 1 (MST1) axis.

Authors:  Yingping Liang; Huanhuan Jie; Qin Liu; Chang Li; Renjie Xiao; Xianliang Xing; Jing Sun; Shuchun Yu; Yanhui Hu; Guo-Hai Xu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 3.  Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment.

Authors:  Bo Zhu; Siu-Lung Chan; Jack Li; Kathryn Li; Hao Wu; Kui Cui; Hong Chen
Journal:  Front Cardiovasc Med       Date:  2021-09-07

Review 4.  Role of Exosomes in Chronic Liver Disease Development and Their Potential Clinical Applications.

Authors:  Chen Wang; Jinwen Liu; Yongmin Yan; Youwen Tan
Journal:  J Immunol Res       Date:  2022-05-06       Impact factor: 4.493

Review 5.  MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Zhiqiang Fang; Guorui Dou; Lin Wang
Journal:  Int J Biol Sci       Date:  2021-04-29       Impact factor: 6.580

6.  Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.

Authors:  Markus Zeitlinger; Birgit C P Koch; Roger Bruggemann; Pieter De Cock; Timothy Felton; Maya Hites; Jennifer Le; Sonia Luque; Alasdair P MacGowan; Deborah J E Marriott; Anouk E Muller; Kristina Nadrah; David L Paterson; Joseph F Standing; João P Telles; Michael Wölfl-Duchek; Michael Thy; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447

Review 7.  Muscles in Winter: The Epigenetics of Metabolic Arrest.

Authors:  W Aline Ingelson-Filpula; Kenneth B Storey
Journal:  Epigenomes       Date:  2021-12-16

8.  IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p.

Authors:  Xudong Ren; Yu Zhou; Yunling Luo; Chaoqun Wang; Anna Pan; Yanqin Ju; Haoting Sun; Zhifei Lin; Beiyuan Hu; Guangzheng Sun; Wenwei Zhu; Liang Hong
Journal:  Gastroenterol Res Pract       Date:  2022-04-06       Impact factor: 2.260

9.  Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis.

Authors:  Yuhan Li; Jing-Jun Nie; Yuhui Yang; Jianning Li; Jiarui Li; Xianxian Wu; Xing Liu; Da-Fu Chen; Zhiwei Yang; Fu-Jian Xu; Yi Yang
Journal:  ACS Appl Mater Interfaces       Date:  2022-07-20       Impact factor: 10.383

Review 10.  Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases.

Authors:  Seonghwan Hwang; Yoon Mee Yang
Journal:  Arch Pharm Res       Date:  2021-06-24       Impact factor: 4.946

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.